HighTower Advisors LLC Increases Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

HighTower Advisors LLC lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,140 shares of the company’s stock after buying an additional 142 shares during the quarter. HighTower Advisors LLC’s holdings in Medpace were worth $1,043,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Centaurus Financial Inc. lifted its position in shares of Medpace by 2.0% in the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock valued at $505,000 after acquiring an additional 29 shares in the last quarter. Lindbrook Capital LLC raised its stake in Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares during the period. Assetmark Inc. lifted its holdings in Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock worth $57,000 after purchasing an additional 29 shares in the last quarter. Proficio Capital Partners LLC lifted its holdings in Medpace by 4.1% in the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock worth $243,000 after purchasing an additional 29 shares in the last quarter. Finally, Schulhoff & Co. Inc. boosted its stake in Medpace by 1.2% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock worth $874,000 after purchasing an additional 30 shares during the period. Institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on MEDP. Leerink Partners initiated coverage on shares of Medpace in a report on Monday. They issued a “market perform” rating and a $330.00 target price on the stock. Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a report on Monday. Nine research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and an average price target of $376.30.

Medpace Price Performance

NASDAQ:MEDP opened at $317.65 on Thursday. The firm has a market capitalization of $9.68 billion, a price-to-earnings ratio of 25.15, a PEG ratio of 3.81 and a beta of 1.47. The business has a 50 day simple moving average of $336.81 and a 200-day simple moving average of $339.41. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.